Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare



  AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare

PR Newswire

REDWOOD CITY, Calif., May 29, 2013

REDWOOD CITY, Calif., May 29, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that Richard King, President and
CEO, will present a corporate overview at the Jefferies 2013 Global Healthcare
Conference at the Grand Hyatt, New York in New York, NY.  The presentation is
scheduled for Tuesday, June 4, 2013 at 1:00 p.m. ET/10:00 a.m. PT.

The presentation will be webcast live and can be accessed through the
Investors page at www.acelrx.com.  For those not available to listen to the
live broadcast, a replay of the presentations will be archived for 90 days and
available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain.  AcelRx's lead product candidate,
the Sufentanil NanoTab PCA System, is designed to solve the problems
associated with post-operative intravenous patient-controlled analgesia which
has been shown to cause harm to patients following surgery because of the side
effects of morphine, the invasive IV route of delivery and the complexity of
infusion pumps.  The NanoTab System has successfully completed all three of
its planned Phase 3 clinical trials and a New Drug Application submission is
planned for the third quarter of 2013.  AcelRx has announced positive top-line
results for a Phase 2 trial for ARX-04, a sufentanil formulation for the
treatment of moderate-to-severe acute pain, funded through a grant from U.S.
Army Medical Research and Materiel Command.  The company has two additional
pain treatment product candidates, ARX-02 and ARX-03, which have completed
Phase 2 clinical development.  For additional information about AcelRx's
clinical programs please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not
limited to, statements related to planned or anticipated future clinical
development of AcelRx Pharmaceuticals' product candidates, and the therapeutic
potential of AcelRx Pharmaceuticals' product candidates.  These
forward-looking statements are based on AcelRx Pharmaceuticals' current
expectations and inherently involve significant risks and uncertainties.
 AcelRx Pharmaceuticals' actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a
result of these risks and uncertainties, which include, without limitation,
risks related to: the success, cost and timing of AcelRx Pharmaceuticals'
product development activities and clinical trials; the market potential for
its product candidates; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission
filings, including its Quarterly Report on Form 10-Q filed with the SEC on May
8, 2013.  AcelRx Pharmaceuticals undertakes no duty or obligation to update
any forward-looking statements contained in this release as a result of new
information, future events or changes in its expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)

SOURCE AcelRx Pharmaceuticals, Inc.

Website: http://www.acelrx.com
Contact: Jim Welch, Chief Financial Officer, 650.216.3511, jwelch@acelrx.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement